SCHEMBL23216786

SCHEMBL23216786

O=C(O)CCNC1(c2ccc(F)c(F)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 5/20 0.45
HDAC3 O15379 4/20 0.45
HDAC1 Q13547 4/20 0.45
HDAC2 Q92769 4/20 0.45
SLC6A4 P31645 3/20 0.38
SLC6A3 Q01959 3/20 0.38
SLC6A2 P23975 2/20 0.38
HSD11B1 P28845 2/20 0.37
CCR2 P41597 1/20 0.36
HCAR3 P49019 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
AKR1C1 Q04828 1/20 0.35
GCGR P47871 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23215202 0.85 HDAC6 (0.47) HDAC6HDAC3HDAC1HDAC2SLC6A4
SCHEMBL23232319 0.81 HDAC3 (0.40) HDAC6HDAC3HDAC1HDAC2SLC6A4
SCHEMBL23216637 0.80 HDAC3 (0.40) HDAC6HDAC3HDAC1HDAC2SLC6A4
SCHEMBL30264905 0.72 HDAC3 (0.42) HDAC6HDAC3HDAC1HDAC2SLC6A4
SCHEMBL28781306 0.72 HDAC3 (0.42) HDAC6HDAC3HDAC1HDAC2SLC6A4
SCHEMBL31036999 0.72 HDAC3 (0.46) HDAC6HDAC3HDAC1HDAC2SLC6A4
SCHEMBL28320840 0.71 GRIN2D (0.57) HDAC6HDAC3HDAC1HDAC2AKR1C1
SCHEMBL433244 0.71 SLC6A3 (0.59) SLC6A4SLC6A3SLC6A2HSD11B1CCR2
SCHEMBL22470441 0.70 KCNN4 (0.43) HDAC6HDAC3HDAC1HDAC2
SCHEMBL8486763 0.69 ALDH1A1 (0.55) GCGRMEN1ALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CONTINEUM THERAPEUTICS, INC. (US) 2026-03-03 US disclosed
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2025-05-29 US disclosed
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS, INC. 2023-03-23 US disclosed
CN-114729044-A Muscarinic acetylcholine M1Receptor antagonists 帕珀莱恩医疗公司 2022-07-08 CN disclosed
WO-2021071843-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS Pipeline Therapeutics, Inc. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CHRM1, CHRM2, CHRM3 HDAC6 1626/4885HDAC3 603/4885HDAC1 766/4885
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 HDAC6 1302/4885HDAC3 729/4885HDAC1 544/4885
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM5, CHRM3 HDAC6 1801/4885HDAC3 525/4885HDAC1 838/4885
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 HDAC6 1291/4885HDAC3 725/4885HDAC1 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.